Thomas Clarke, Ph.D.
About Thomas Clarke, Ph.D.
Thomas Clarke, Ph.D., is a Postdoctoral Research Fellow currently affiliated with Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of MIT and Harvard. His research focuses on post-translational modifications and their impact on genome stability, with the goal of developing new cancer treatment strategies.
Current Work at Broad Institute
Thomas Clarke, Ph.D., has been a Postdoctoral Research Fellow at the Broad Institute of MIT and Harvard since 2021. He conducts research in Cambridge, Massachusetts, focusing on post-translational modifications and their implications for genome stability. His work aims to contribute to the development of new therapeutic strategies for cancer treatment by leveraging mechanistic insights gained through his research.
Research at Massachusetts General Hospital
Since 2017, Thomas Clarke has held the position of Postdoctoral Research Fellow at Massachusetts General Hospital in the Greater Boston Area. He works in the laboratory of Dr. Raul Mostoslavsky, where he investigates the role of post-translational modifications in genome stability. His research is directed towards understanding these mechanisms to inform cancer treatment strategies.
Education and Expertise
Thomas Clarke earned his Doctor of Philosophy (Ph.D.) in Oncology and Cancer Biology from the University of Birmingham, where he studied from 2013 to 2017. Prior to this, he obtained a Bachelor of Science (B.Sc.) in Medical Sciences (With Professional Training) from the University of Exeter, completing his studies from 2009 to 2013. Additionally, he served as a Visiting Research Scholar at Harvard University from 2011 to 2012.
Previous Experience at University of Birmingham
Before his current roles, Thomas Clarke was a Ph.D. Candidate at the University of Birmingham from 2013 to 2017. During this four-year period, he engaged in research that laid the foundation for his expertise in oncology and cancer biology, ultimately leading to his doctoral degree.